Clinical Report: The Therapeutic Potential of Targeting IL-17 in Tissue Repair
Overview
IL-17 plays a dual role in tissue repair, promoting healing in the acute phase while potentially exacerbating fibrosis in chronic conditions. This review synthesizes recent findings on the regulatory mechanisms of IL-17 across various tissues, highlighting its therapeutic implications.
Background
Understanding the role of IL-17 in tissue repair is crucial due to its involvement in both promoting and hindering healing processes. The cytokine's biphasic effects can significantly influence clinical outcomes in conditions characterized by inflammation and fibrosis. This review aims to clarify the contexts in which IL-17 can be targeted therapeutically.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
IL-17 accelerates tissue repair by promoting epithelial regeneration and angiogenesis in the acute phase.
Excessive IL-17 activation in the chronic phase can lead to uncontrolled inflammation and fibrosis progression.
The effects of IL-17 are tissue-specific, showing significant heterogeneity across organs like skin, lungs, and intestines.
Cellular origin, injury phase, and local microenvironment are critical determinants of IL-17's dual roles.
Current evidence remains largely organ-specific and fragmented, necessitating a holistic understanding of IL-17's functions.
Clinical Implications
Clinicians should consider the timing and context of IL-17 activation when developing treatment strategies for tissue repair. Targeting IL-17 may be beneficial in acute injury scenarios, while caution is warranted in chronic conditions to avoid exacerbating fibrosis.
Conclusion
IL-17's dual role in tissue repair underscores the need for tailored therapeutic approaches that consider the specific clinical context and tissue environment.
